Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.68B 2.36B 2.19B 2.01B 3.78B 258B 3.83B 26.01B 10.16B 127B 10.07B 9.85B 439B P/E 2026 *
104x
P/E 2027 * 30.9x
Enterprise Value 2.68B 2.36B 2.19B 2.01B 3.78B 258B 3.83B 26.01B 10.16B 127B 10.07B 9.85B 439B EV / Sales 2026 *
3.09x
EV / Sales 2027 * 2.62x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day-2.10%
1 week-3.83%
Current month-0.67%
1 month+2.35%
3 months-7.15%
6 months-4.25%
Current year-7.04%
1 week 46.03
Extreme 46.03
48.79
1 month 44.75
Extreme 44.75
51.37
Current year 42.45
Extreme 42.45
59.68
1 year 32.83
Extreme 32.83
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Compliance Officer 63 31/12/2011
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap.
16/03/26 Fiscal year

Chief Technology Officer

321,750 0.5738%
13/03/26 Others

Founder

60,000 0.1070%
12/03/26 Sell

Director

5,369 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
-2.10%-3.83%+40.64%+53.74% 2.74B
+0.45%+2.80%+55.83%+20.48% 322B
-0.07%+2.09%+22.76%-11.68% 68.84B
+1.35%+5.29%+39.41%+91.60% 9.59B
+0.93%-1.38%+1.71%-4.10% 8.29B
+1.13%+1.51%-20.98%-4.73% 4.23B
-4.00%+0.71%-7.10%+12.39% 3.77B
+4.90%+5.79%-39.25%+19.34% 3.61B
-4.07%-2.45%-3.76%-17.52% 2.13B
-5.78%+0.89%-18.97%+28.59% 1.96B
Average -0.73%+0.85%+7.03%+18.81% 42.74B
Weighted average by Cap. +0.33%+2.14%+46.23%+16.15%

Financials

2026 *2027 *
Net sales 867M 762M 708M 650M 1.22B 83.51B 1.24B 8.41B 3.29B 41.06B 3.26B 3.19B 142B 1.02B 898M 835M 767M 1.44B 98.51B 1.46B 9.92B 3.88B 48.43B 3.84B 3.76B 167B
Net income 25.92M 22.77M 21.17M 19.43M 36.51M 2.5B 37.07M 251M 98.24M 1.23B 97.32M 95.22M 4.24B 92.99M 81.68M 75.96M 69.7M 131M 8.96B 133M 902M 352M 4.4B 349M 342M 15.22B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
24/07/26 US$46.20 -2.10% 521,934
23/07/26 US$47.19 +0.53% 463,337
22/07/26 US$46.94 -1.94% 430,060
21/07/26 US$47.87 +0.95% 450,290
20/07/26 US$47.42 -1.29% 618,820
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
46.20USD
Average target price
63.50USD
Spread / Average Target
+37.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock